Multidomain Approach Through Biopsychosocial Pathways (MAP) Intervention for Older Adults With Age-Related Hearing Loss

November 11, 2026 updated by: The Hong Kong Polytechnic University

Development and Preliminary Evaluation of a Multidomain Approach Through Biopsychosocial Pathways (MAP) Intervention for Older Adults With Age-Related Hearing Loss: Pilot Randomized Controlled Trial

Background With population aging accelerating worldwide, age-related hearing loss (ARHL) has become one of the most prevalent sensory impairments among older adults, with global prevalence rising from 12.7% at age 60 to over 58% by age 90. The communication difficulties, reduction in daily-life activities, and social stigma associated with hearing loss can contribute to increased loneliness in older adults. This condition affects approximately 25% of older adults in mainland China and 46% in Hong Kong and is associated with depression, increased mortality risk, and elevated healthcare utilization. Addressing loneliness in this population is therefore essential not only for older adults' own health and wellbeing, but also for promoting healthy aging and sustainable community-based care. However, limited studies have examined the associations between loneliness and physical, psychosocial, and hearing health status among older adults with ARHL in real-life living environments and no qualitative study has explored their perceptions and experiences of loneliness. The built environment may influence both hearing health and loneliness among older adults by shaping communication opportunities, social participation, mobility, and access to supportive resources. Therefore, examining the relationships among loneliness, hearing difficulties, and the built environment is important for understanding how everyday living contexts contribute to or mitigate loneliness in later life. Furthermore, existing intervention studies have concentrated mainly on hearing aids and cochlear implants. However, loneliness in this population arises not only from reduced auditory input, but also from psychological distress, social exclusion, and limited opportunities for social engagement, all of which are factors that hearing correction alone cannot directly resolve. These gaps limit the evidence base needed to understand and address loneliness in this population and hinder the development of multi-component interventions for older adults with ARHL.

Aim This study aims 1) to explore the perceptions and experiences of loneliness and social engagement among older adults with ARHL; 2) to examine the associations between loneliness and physical, psychosocial, hearing health, and built environment factors; and 3) to develop and preliminarily evaluate a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention to address loneliness in this population.

Methods A sequential exploratory mixed methods design was adopted, underpinned by the Socio-Ecological Model. This study will be conducted in three phases. First, a qualitative descriptive methodology was used among community-dwelling older adults with ARHL to explore their perceptions and experiences of loneliness and social engagement. Second, a cross-sectional study, with GIS-based spatial analysis will be conducted to examine the associations between loneliness and physical, psychosocial, hearing health, and built-environment factors. Last, a pilot randomized controlled trial will be conducted to evaluate the feasibility, acceptability, and preliminary effects of MAP, underpinned by the biopsychosocial model and findings of previous phases to reduce loneliness among older adults with ARHL.

Expected outcomes This study is expected to 1) provide in-depth qualitative evidence on the perceptions and experiences of loneliness and social engagement among older adults with ARHL; 2) identify multilevel correlates of loneliness, spanning physical, psychosocial, hearing health, and built environment factors; 3) evaluate the feasibility, acceptability, and preliminary effects of MAP on loneliness, thereby informing the design of a future definitive trial and community-based service planning for this population.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. aged 60 years or older and living in the community;
  2. mild-to-moderate hearing loss, defined as a pure-tone average (PTA) of 20-50 dB across octave frequencies from 0.5 to 4 kHz in both ears;
  3. experiencing loneliness (De Jong Loneliness Scale score ≥ 3);
  4. willingness and ability to provide informed consent and comply with study procedures.

Exclusion Criteria:

  1. a history of psychosis, mania, bipolar disorder, substance use disorder, or suicidal ideation;
  2. severe or unstable medical illness;
  3. significant retro cochlear pathology or an organic lesion causing hearing loss;
  4. a diagnosis of probable Alzheimer disease, vascular dementia, frontotemporal dementia, or Parkinson disease;
  5. regular engagement in mindfulness or other mind-body practices (>2 times weekly).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multidomain Approach through Biopsychosocial Pathways (MAP) intervention

The intervention group will receive a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention comprising self-administered auricular acupressure, video-guided mindfulness practice adapted from Mindfulness-Based Stress Reduction (MBSR), and a GIS-guided community engagement programme, delivered concurrently over an 8-week period.

The intervention group will receive a Multidomain Approach through Biopsychosocial Pathways (MAP) intervention comprising self-administered auricular acupressure, video-guided mindfulness practice adapted from Mindfulness-Based Stress Reduction (MBSR), and a GIS-guided community engagement programme, delivered concurrently over an 8-week period.

Placebo Comparator: Control group

The control group will receive reading materials on ARHL, loneliness, and hearing health education. The control group will receive delayed access to the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention after completion of the final follow-up assessment.

The control group will receive reading materials on ARHL, loneliness, and hearing health education. The control group will receive delayed access to the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention after completion of the final follow-up assessment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to the three intervention components
Time Frame: Throughout the 8-week intervention period

Intervention adherence rates for the three components (Auricular acupressure self-administration, completion rate of weekly video-guided mindfulness sessions, and engagement with the GIS-guided community engagement programme) will be assessed using self-reported logs completed independently by older participants via paper booklets. For each component, adherence will be calculated as the number of completed sessions divided by the total number of prescribed sessions during the 8-week intervention period, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater adherence to the respective intervention schedule.

Throughout the 8-week intervention period
Usage Frequency to the three intervention components
Time Frame: Throughout the 8-week intervention period

The adherence to the three intervention components was assessed using self-reported logs completed independently by older participants via paper booklets. A usage session was defined as one recorded episode of engaging in each respective activity. Adherence for each component was quantified as the mean number of sessions completed per week across the 8-week intervention period, with higher values indicating more frequent engagement.

Throughout the 8-week intervention period
Participant retention rate
Time Frame: Week 8

The participant retention rate will be calculated as the number of enrolled participants who remain in the study and have not withdrawn by Week 8 divided by the total number of participants enrolled, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater participant retention.

Week 8
The follow-up assessment completion rate
Time Frame: Week 8

The follow-up assessment completion rate will be calculated as the number of participants who complete the scheduled Week 8 follow-up assessment divided by the total number of enrolled participants expected to complete the assessment, multiplied by 100. Scores range from 0% to 100%, with higher percentages indicating greater follow-up completion.

Week 8
Acceptability of the intervention assessed by semi-structured interviews
Time Frame: Week 8, following completion of the intervention

All participants in the intervention group will be invited to take part in an individual interview after completing the intervention, to explore their experiences of participating in the Multidomain Approach through Biopsychosocial Pathways (MAP) intervention and their perceptions of its acceptability. Interview data will be analyzed using thematic analysis and reported as themes and subthemes related to participants' experiences and perceived acceptability. No numerical scale score will be calculated.

Week 8, following completion of the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Loneliness
Time Frame: Baseline and Week 8

Loneliness will additionally be assessed as a preliminary indicator of intervention effect. This is the outcome proposed as the primary outcome for a future definitive trial. Change in loneliness from baseline to post-intervention will be measured using the Mandarin version of the 6-item De Jong Gierveld Loneliness Scale (DJGLS).

Baseline and Week 8
Sleep quality
Time Frame: Baseline and Week 8

Sleep quality will be assessed using the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI), administered at baseline and post-intervention.

Baseline and Week 8
Subjective hearing difficulty
Time Frame: Baseline and Week 8

Subjective hearing difficulty will be measured using the 18-item Revised Hearing Handicap Inventory (R-HHI), administered at baseline and post-intervention.

Baseline and Week 8
Depressive symptoms
Time Frame: Baseline and Week 8

Depressive symptoms will be screened with the Patient Health Questionnaire-2 (PHQ-2), administered at baseline and post-intervention.

Baseline and Week 8
Community resource utilization
Time Frame: Baseline and Week 8

As no validated instrument exists for this intervention-specific component, a study-designed weekly tick-box log will be used to record visits to GIS-recommended resources (hearing service centers or community/green space facilities), with participants choosing a paper or electronic format based on preference. Logs will be submitted at the post-intervention assessment, with paper records transcribed into the same database as electronic entries. The primary metric will be the cumulative number of resource visits over the intervention period.

Baseline and Week 8

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

June 30, 2028

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • S001975

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.